Treatment for Hepatitis C
  Hepatitis C Articles

Treatment for Hepatitis B
  Hepatitis B Articles
  Hepatitis B Library of Slides and Posters

Treatment for HIV-HCV Coinfection
  HIV-HCV Coinfection Articles

Treatment for Hepatitis C

DDW 2006 - Hepatitis C Treatment Articles

Hepatitis C Treatment for Patients with Thalassemia and Sickle-Cell Disease - 6/20/06

Treating Hepatitis C in Patients with Pre-Existing Psychiatric Conditions - 6/16/06

High Response Rates in Naïve Patients Treated with Pegylated Interferon Plus Ribavirin - 6/16/06

Steatosis Linked to Severe Fibrosis and Liver Cancer in Patients with Hepatitis C - 6/16/06

Natural History of Liver Cirrhosis Due to Hepatitis C - 6/16/06

Virahep-C Clarifies Reasons for Lower Response Rates Among African American Patients - 6/13/06

Early Response Does Not Predict Sustained Response Among African Americans - 6/13/06

African Americans More Likely to Have Normal ALT, Less Fibrosis - 6/13/06

Implications of Normal ALT and Initially Mild Liver Disease - 6/13/06

Lower Treatment Response Rates in Hispanic Patients - 6/13/06

Promising Data on Consensus Interferon Retreatment of Relapsers and Non-Responders - 6/09/06

Albuferon Demonstrates Promising Antiviral Activity in Prior Non-Responders - 6/09/06

Eltrombopag Improves Thrombocytopenia in Patients with Cirrhosis - 6/09/06
Blood Cell Growth Factors Improve Adherence and SVR Rates - 6/06/06

CPG 10101: Promising Data at 12 Weeks in Prior Relapsers - 6/06/06

Celgosivir: Well-Tolerated, but Minimal Anti-HCV Activity as Monotherapy - 6/06/06

Factors Influencing Treatment Response in WIN-R Trial- 6/02/06

Preclinical Data on New HCV Protease Inhibitor ITMN 191- 6/02/06

Detection of HCV RNA Using Sensitive Test Can Help Guide Therapy- 5/30/06

Predictors of Sustained Response to Peg-Intron or Pegasys Plus Ribavirin - 5/30/06

Polymerase Inhibitor HCV-796 Demonstrates Potent Antiviral Activity- 5/30/06

In Nonresponders to Peginterferon/Ribavirin, Valopicitabine + Peginterferon at Optimal Dosing Produces Significantly Greater HCV Suppression Compared to Retreatment with Peginterferon Alfa- 5/26/06

12 of 12 Patients Receiving Experimental HCV Protease Inhibitor VX 950 in Combination with Pegasys Plus Ribavirin for 28 Days Experience Undetectable HCV RNA Levels- 5/23/06

Retreatment with Peginterferon Alfa-2a (Pegasys) Plus Ribavirin of Nonresponders with Cirrhosis/Advanced Fibrosis to Peginterferon Alfa-2b (PegIntron) - 5/23/06

Differences in Outcomes of Treatment with PegIntron Plus Fixed-dose or Weight-based Ribavirin Based on Genotype and Viral Load in HCV Genotypes 2 and 3 in The WIN-R Trial - 5/23/06

Cost-Effectiveness of First-Line Pegasys Plus Ribavirin in Patients with Mild Chronic Hepatitis C (CHC) in the US - 5/23/06

The Effect of Liver Fibrosis and Cirrhosis on SVR in 4913 Patients with Hepatitis C: Results from the Win-R Trial - 5/23/06

Initial HCV Response in Patients with End Stage Renal Disease Treated with Pegasys Plus Ribavirin - 5/23/06

Evaluation of a HCV Patient Support Program’s Impact on Patient Adherence - 5/23/06

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week 2006 (DDW 2006) 37th Annual Meeting in Los Angeles - 5/19/06

Treatment for Hepatitis B

DDW 2006 - Hepatitis B Library of Slides and Posters

A Randomized Trial of Telbivudine (LdT) vs. Adefovir for HBeAg-Positive Chronic Hepatitis B: Results of the Primary Week 24 Analysis E. Heathcote. Abstract 479.

Final Analysis of Virological Outcomes and Resistance During 5 Years of Adefovir Dipivoxil Monotherapy in HBeAg- Negative Patients K. Borroto-Esoda. Abstract 477.

Safety and Efficacy of Adefovir Dipivoxil in Patients with Lamivudine- Resistant
Chronic Hepatitis B undergoing Liver Transplantation E. Schiff. Abstract 480.

Durability of HBeAg Seroconversion Following Adefovir Dipivoxil Treatment for Chronic Hepatitis B T. Chang and others.

Predictive Factors for Exacerbation of Hepatitis B After Discontinuation of Oral
Therapy in HBeAg- Negative Patients Y. Murata. Abstract 481.

Entecavir is Associated with an Improvement in Liver Histology and a Reduction in HBV DNA in Patients with Lamivudine-Refractory HBeAg(+) Regardless of Baseline Characteristics M.L. Shiffman and others

Continued Virologic and Biochemical Improvement Through 96 Weeks of Entecavir Treatment in HBeAg(-) Chronic Hepatitis B Patients (Study ETV-027) F. Poordad and others

Modeling Clinical Benefits of Suppressing Viral Replication in HBeAg (-) Chronic Hepatitis B Patients: A Number-Needed-to-Treat Analysis of Entecavir and Adefovir U. Iloeje and others

Predicting Liver Disease Complications (HCC and Cirrhosis) in Patients with Chronic Hepatitis B Infection: The R.E.V.E.A.L.- HBV Study Chen and others

Cost-effectiveness of Antivirals in HBeAg-positive Chronic Hepatitis B:Impact of Seroconversion and Viral Suppression D. Veenstra and others

DDW 2006 - Hepatitis B Treatment Articles

Nitzoxanide Demonstrates In Vitro Activity Against HBV - 6/16/06

HBV Vaccine Induces CD3, CD4, and CD25 Activity, Provides Long-Lasting Protection - 6/16/06

Long-Term Benefits of Hepatitis B Treatment in HBeAg-Negative Patients - 6/13/06

Treatment of Multidrug-Resistant Hepatitis B - 6/13/06

Occurrence of Adefovir-Resistance Mutations in Lamivudine-Resistant Hepatitis B Patients - 6/13/06

Durability of HBeAg Seroconversion After Adefovir Treatment - 6/09/06

Hepatitis B Virological Breakthrough During Lamivudine Therapy - 6/09/06

Cost Effectiveness of Hepatitis B Treatment with Antiviral Agents - 6/09/06

Risk Factors for Hepatitis Flares After Discontinuing Adefovir - 6/09/06

Tenofovir More Potent than Adefovir Against Lamivudine-Resistant HBV - 6/06/06

Factors Associated with Progression to Cirrhosis and Liver Cancer - 6/06/06

Final Five-Year Outcome and Resistance Data on Adefovir Monotherapy- 6/02/06

Adefovir Plus Lamivudine After Liver Transplantation in Hepatitis B Patients- 6/02/06

Telbivudine Demonstrates Greater Antiviral Efficacy than Adefovir at 24 Weeks- 5/30/06

Entecavir is Associated with Improved Liver Histology and Reduced HBV DNA in Patients with Lamivudine-Resistant Virus- 5/30/0

94% of Hepatitis B Patients Receiving Entecavir Experience Undetectable HBV Viral Load Compared to 77% of Patients Receiving Lamivudine- 5/26/06

Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B:  Response at 1 Year -5-23-06

DDW 2006 - HIV-HCV Coinfection Treatment Articles

Severe Liver Disease Associated with Prolonged Antiretroviral Therapy - 6/13/06

Impact of HIV Coinfection on Steatosis in Patients with Hepatitis C - 6/09/06

Growth Factors for Neutropenia and Anemia Effective in Coinfected Patien - 6/06/06

Meta-Analysis of Treatment of Chronic Hepatitis C in HIV-Positive Patients - 6/02/06

ddw 2006 ddw 2006 ddw 2006 ddw 2006 ddw 2006 ddw 2006 ddw 2006 ddw 2006 ddw 2006 ddw 2006 ddw 2006 ddw 2006 ddw 2006 ddw 2006